WO2022179905A1 - Composition et kit pour soulager les symptômes de l'allergie respiratoire chez les jeunes enfants - Google Patents

Composition et kit pour soulager les symptômes de l'allergie respiratoire chez les jeunes enfants Download PDF

Info

Publication number
WO2022179905A1
WO2022179905A1 PCT/EP2022/053781 EP2022053781W WO2022179905A1 WO 2022179905 A1 WO2022179905 A1 WO 2022179905A1 EP 2022053781 W EP2022053781 W EP 2022053781W WO 2022179905 A1 WO2022179905 A1 WO 2022179905A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
use according
kit
epicatechin
individual
Prior art date
Application number
PCT/EP2022/053781
Other languages
English (en)
Inventor
Carine Blanchard
Sébastien HOLVOET
Original Assignee
Société des Produits Nestlé S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Société des Produits Nestlé S.A. filed Critical Société des Produits Nestlé S.A.
Priority to JP2023548866A priority Critical patent/JP2024506678A/ja
Priority to EP22707068.7A priority patent/EP4297736A1/fr
Priority to AU2022224953A priority patent/AU2022224953A1/en
Priority to US18/547,277 priority patent/US20240139264A1/en
Publication of WO2022179905A1 publication Critical patent/WO2022179905A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • the present invention relates to a composition for use in the prevention of respiratory allergy, in particular allergic rhinitis, dust mite allergy and/or asthma.
  • the invention also provides a kit comprising a combination of at least one polyphenol and at least one probiotic selected from the group consisting of Lactobacillus paracasei and Lactococcus lactis in one or more containers.
  • Nutritional interventions to prevent the development or to manage the symptoms of allergic diseases are a promising alternative to medications and have been assessed in numerous pre-clinical and clinical settings.
  • probiotic bacteria Korean et al. , Lancet. 2001, 357:1076-9.
  • prebiotics Arslanoglu et al. 2008, J Nutr 138:1091-1095
  • poly-unsaturated fatty acids Dunstan et al. 2003, J Allergy Clin Immunol 112: 1178-1184) have been documented.
  • EP 2747584 from the same applicant, relates to epicatechin for use in the prevention or reduction of symptoms of an allergic disorder and/or an allergic reaction.
  • probiotic strains have been described to play an important role in the gut microbiota and to be associated with positive health effects. They can promote good digestion, boost the immune system, and produce lactic and acetic acid that controls intestinal pH.
  • Various probiotic cultures or mixes of probiotics have been described for their effect on the allergic immune system: for example, EP185833, describes a mix of probiotics that can decrease the risk of allergies due to wheat flour albumin and globulins.
  • WO 2009/072889 describes a Bifidobacterium that can be used in improving the lung function of subjects suffering from dust mite allergy.
  • the new solution should not have adverse health or side- effects upon a prolonged consumption, and the compound should ideally be available from a natural source and in amounts, which would make it practical and feasible to be consumed by an individual for example as part of a daily diet in a high enough dose for being effective.
  • the object of the present invention is to improve the state of the art and to provide a new and alternative solution for preventing and/or reducing the symptoms of respiratory allergy disorder or related allergic reaction.
  • the object of the present invention is achieved by the subject matter of the independent claims.
  • the dependent claims further develop the idea of the present invention.
  • the present invention provides in a first aspect at least one probiotic selected from the group consisting of Lactobacillus paracasei and Lactococcus lactis, and at least one polyphenol for use in treating and/or preventing and/or alleviating respiratory allergy symptoms and/or a respiratory allergy reaction in an individual, in particular a toddler.
  • the present invention provides a kit comprising a combination of at least one polyphenol and at least one probiotic selected from the group consisting of Lactobacillus paracasei and Lactococcus lactis in one or more containers.
  • a disclosure of from 1 to 10 should be construed as supporting a range of from 1 to 8, from 3 to 7, from 1 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.
  • the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise.
  • reference to “a metabolite” or “the metabolite” includes one metabolite but also two or more metabolites.
  • compositions disclosed herein may lack any element that is not specifically disclosed herein.
  • a disclosure of an embodiment using the term “comprising” includes a disclosure of embodiments “consisting essentially of” and “consisting of” the components identified.
  • X and/or Y should be interpreted as “X,” or ⁇ ,” or “X and Y.” Similarly, “at least one of X or Y” should be interpreted as “X,” or ⁇ ,” or “both X and Y.”
  • example and “such as,” particularly when followed by a listing of terms, are merely exemplary and illustrative and should not be deemed to be exclusive or comprehensive.
  • association with and “linked with” mean occurring concurrently, preferably means caused by the same underlying condition, and most preferably means that one of the identified conditions is caused by the other identified condition.
  • compositions mean a product or composition that is intended for ingestion by an individual such as a human and provides at least one nutrient to the individual.
  • compositions of the present disclosure can comprise, consist of, or consist essentially of the elements disclosed herein, as well as any additional or optional ingredients, components, or elements described herein or otherwise useful in a diet.
  • treat and “treatment” mean to administer a composition as disclosed herein to a subject having a condition in order to lessen, reduce or improve at least one symptom associated with the condition and/or to slow down, reduce or block the progression of the condition.
  • treatment and “treat” include both prophylactic or preventive treatment (that prevent and/or slow the development or progression of a targeted pathologic condition or disorder) and curative, therapeutic, or disease-modifying treatment, including therapeutic measures that cure, slow down, lessen symptoms of, and/or halt the progression of a diagnosed pathologic condition or disorder; and treatment of patients at risk of contracting a disease or suspected to have contracted a disease, as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition.
  • treatment and “treat” do not necessarily imply that a subject is treated until total recovery.
  • treatment also refer to the maintenance and/or promotion of health in an individual not suffering from a disease but who may be susceptible to the development of an unhealthy condition.
  • treatment and “treat” are also intended to include the potentiation or otherwise enhancement of one or more primary prophylactic or therapeutic measures.
  • a treatment can be performed by a patient, a caregiver, a doctor, a nurse, or another healthcare professional.
  • toddler means a child aged between one and less than three years.
  • the at least one polyphenol and at least one one probiotic selected from the group consisting of Lactobacillus paracasei and Lactococcus lactis are administered in a serving or unit dosage form that provides a therapeutically effective or prophylactically effective amount.
  • prevention means to administer a composition as disclosed herein to a subject is not showing any symptoms of the condition to reduce or prevent development of at least one symptom associated with the condition. Furthermore, “prevention” includes reduction of risk, incidence and/or severity of a condition or disorder.
  • an “effective amount” is an amount that treats or prevents a deficiency, treats or prevents a disease or medical condition in an individual, or, more generally, reduces symptoms, manages progression of the disease, or provides a nutritional, physiological, or medical benefit to the individual.
  • the term “pet” means any animal which could benefit from or enjoy the compositions provided by the present disclosure.
  • the pet can be an avian, bovine, canine, equine, feline, hircine, lupine, murine, ovine, or porcine animal, but the pet can be any suitable animal.
  • the term “companion animal” means a dog or a cat.
  • oral nutrition supplement is a composition comprising at least one macronutrient and/or at least one micronutrient, for example in a form of sterile liquids, semi-solids or powders, and intended to supplement other nutritional intakes such as that from food.
  • kits means that the components of the kit are physically associated in or with one or more containers and considered a unit for manufacture, distribution, sale, or use.
  • Containers include, but are not limited to, bags, boxes, cartons, bottles, packages of any type or design or material, over-wrap, shrink-wrap, affixed components (e.g., stapled, adhered, or the like), or combinations thereof.
  • allergic rhinitis also commonly known as pollenosis or hay fever
  • pollenosis refers herein to an allergic inflammation of the nasal airways and characterized by blocked and runny nose, sneezing and itching. Ocular symptoms such as red and watery eyes can also manifest. It occurs when an allergen, such as pollen or dust mite, is inhaled by an individual with a sensitized immune system. In such individuals, the allergen triggers the production of the antibody immunoglobulin E (IgE).
  • IgE antibody immunoglobulin E
  • asthma refers herein to the common chronic inflammatory disease of the lower airways and is characterized by wheezing, mucus production and impaired lung function.
  • Plant polyphenols in the sense of the invention are phenols comprising more than 2 phenolic groups.
  • the present invention pertains to a composition
  • a composition comprising at least one probiotic selected from the group consisting of Lactobacillus paracasei and Lactococcus lactis and at least one polyphenol for use in treating and/or preventing and/or alleviating respiratory allergy symptoms and/or a respiratory allergy reaction in an individual, in particular a toddler.
  • Examples of specific allergic disorders may be allergic rhinitis, dust mite allergy or asthma.
  • the composition of the present invention may thus be for use in the treatment or prevention of an allergic disorder, wherein the allergen trigger is an environmental allergen, preferably selected from one or more of: dust mite, pollen, molds or mold spores, weed pollen, tree pollen, grass pollen, fleas, pet hair, feathers or pet dander.
  • the subject to be treated is preferably a mammal, preferably a human or a companion animal (pet), preferably wherein the subject is a child, an infant, an adolescent or an adult human, a dog, a puppy, a cat or a kitten.
  • the individual is a person suffering from pollen allergy. In a most preferred embodiment, the individual is a toddler.
  • the composition can be administered to a human being of all ages.
  • administration of the composition to a patient starts as soon as an allergy and its symptoms start to manifest, i.e. in many instances already early in life.
  • the human being is a young child between the age of 4 months and six years or an older child up to the age of 18 years or an adult person.
  • the composition is intended for consumption by an animal, preferably a cat or a dog.
  • allergies and symptoms of such allergies can be observed with animals, in particular with domesticated animals and animals kept as pets.
  • the current invention provides a solution that can be provided to a companion animal by his owner.
  • the composition is effective for preventing and/ or alleviating symptoms of respiratory allergy.
  • symptoms may be sneezing, stuffy nose, asthma, fatigue or tiredness, anxiety, sleep disorder.
  • Symptoms associated with respiratory allergy are also mood swings / mood disorders, anxiety, and /or depression.
  • the present composition may thus further provide beneficial effects on such associated disorders.
  • composition according to the present invention further supports the immune system, in particular before and during pollen season.
  • composition according to the present invention comprises at least one polyphenol.
  • Polyphenols are a large group of small compounds with anti-oxidant activity that are commonly found in plants and fruits. Flavonoids are a sub-group of such polyphenols with shared structural features that themselves can be further sub-grouped for example into flavonols, flavanols, flavones, flavanones, and others.
  • the plant phenols can be comprised in plant extracts.
  • the invention also relates to a composition comprising plant extracts containing such polyphenols. Apples are rich in various polyphenols, including quercetin and phlorizidin; green tea is rich in different flavanols including procyanidins and gallated derivatives of catechins and epicatechins.
  • the composition can comprise at least one, at least two, at least three, or at least four different polyphenols.
  • natural sources of polyphenols can be apple, thyme, pomegranate, berries, green coffee, or mixtures thereof.
  • the polyphenols may be extracted from natural plant sources by any known extraction technique, like an extraction with water or an organic solvent, like ethanol or ether.
  • the polyphenol is an epicatechin.
  • Plant or fruit extracts rich in epicatechin or extracts supplemented with epicatechin or epicatechin in isolated or synthesized form per se can be used. No undesired side-effects e.g. resulting from a strong corticosteroid or anti-histaminic activity are expected from a moderate use of epicatechin.
  • plant or fruit extracts can be prepared which are on one hand effective for reducing allergy symptoms and on the other hand still pleasant for consumption. It is now also possible to provide extracts with the appropriate concentration of the active ingredient epicatechin that can be consumed in reasonable and feasible amounts per day e.g. as part of a daily diet by a consumer.
  • the epicatechin is provided in the form of a plant extract or concentrate. This allows providing the epicatechin in its natural form and environment but in concentrated condition. Thereby, the epicatechin is of natural origin and can be provided in a food product that is well recognized and appreciated by a consumer and still provide him with the necessary amount of active epicatechin.
  • a further advantage is that the epicatechin does not need to be first produced in purified form, e.g. via chemical synthesis, and hence provides also a more economic solution for providing the epicatechin to a consumer.
  • the epicatechin is provided in the form of a plant extract which naturally already contains substantial levels of epicatechin and which are well-liked by the consumers.
  • the plant extract or concentrate can preferably be an extract or concentrate from apple, cocoa or tea.
  • the extract is from apple.
  • the epicatechin is provided in the form of a composition comprising at least 0.1 wt%, preferably at least 1 wt% epicatechin.
  • the epicatechin is provided in the form of a composition comprising at least 10 wt%, for example at least 20 wt% or 40 wt%.
  • the composition can be enriched with epicatechin either by concentrating the already naturally present epicatechin therein or supplementing the composition with for example a plant extract rich in epicatechin or with synthetically produced epicatechin.
  • the resulting composition comprises epicatechin in such an amount that it is effective upon a normal, feasible daily consumption of said composition, for example, if part of a food product.
  • the composition which may be consumed between meals as a supplement and not as part of a regular meal.
  • the epicatechin is administered to a human being in an amount in the range from 25 mg to 10 g per day, from 50 mg to 10 g per day, preferably from 100 mg to 5 g per day, even more preferably from 300 mg to 1 g per day. These preferred doses allow providing on one hand sufficient epicatechin to a relevant patient per day to provide the expected health benefit and on the other hand not to overdose epicatechin to prevent the risk of any potential undesirable or toxic effects to the patient.
  • the composition also contains at least one one probiotic selected from the group consisting of Lactobacillus paracasei and Lactococcus lactis strain.
  • the Lactobacillus paracasei is LP-33® or NCC 2461 (CNCM 1-2116), for example.
  • the Lactococcus lactis strain is NCC 2287 (CNCM 1-4154), for example. This is intended to include the bacterium, parts of the bacterium and/or a growth medium fermented by the bacterium.
  • the composition comprises between 10 4 and 10 12 colony forming units (CFU) per g of the dry composition. This amount may either be as a single dose, or spread across multiple doses.
  • CFU colony forming units
  • the amount of probiotic in the infant formula can be between 10 5 and 10 8 CFU/g of infant formula.
  • the composition is provided in the form of chewable tablet it may contain two billion Colony Forming Units (2 x 10 9 CFU) of the strain, in particular of LP-33®.
  • the probiotic strain can be mixed together with the dry or wet composition of the invention. Treatments or specific processes can be applied to improve the stability or viability of the probiotics in the composition. After mixing the probiotic with the composition the mix can be processed in a way that does not dramatically affect the viability of the probiotics.
  • the probiotics are partly or fully inactivated before, during, or after the mixing.
  • the probiotics have been rendered inactivated and/or incapable to replicate prior to the use in the composition of the invention. This for example can be achieved by heat treatment or other known treatments in the art.
  • the composition may further comprise Vitamin C, antioxidants and/ or other bioactive ingredients.
  • Vitamin C may be provided as a natural source, e.g. from acerola extract.
  • the amount provided daily depends on the age of the individual. The average daily recommended amount for an adult is between 75 to 90 mg.
  • the composition may provide at least 15% of the daily intake, up to 120% of the daily intake. Preferably, it provides 15 to 100% of the daily intake.
  • composition for use of the invention is provided in the form of a composition, which is a food product, a food supplement or a pharmaceutical product.
  • the composition may be selected from the group consisting of a food composition, a pet food composition, a dietary supplement, a nutraceutical, a nutritional formula, a drink, and/or a medical composition.
  • food compositions that are applicable to the present invention are yoghurts, milk, flavored milk, ice cream, ready to eat desserts, powders for reconstitution with, e.g., milk or water, chocolate milk drinks, malt drinks, ready-to-eat dishes, instant dishes, or drinks for humans or food compositions representing a complete or a partial diet intended for pets or livestock. Consequently, in one embodiment the composition according to the present invention is a food product intended for humans, pets or livestock, and preferably humans and pets. In a preferred embodiment, the composition is a food product, or a dietary supplement intended for humans (infant, child, adolescent, or adult) or companion animals (pets) (preferably dog, puppy, cat or kitten).
  • the food product is a food for specific medical purposes such as a health care food product for oral feeding, and/or a nutritional product for enteral feeding.
  • the advantage of the invention is that the active ingredient polyphenol (preferably epicatechin) can be provided in relatively high local concentrations and low volumes of a medical food product and hence be administered effectively to patients in such need.
  • the food product is selected from the group consisting of an infant feeding composition, a follow-up formula, a growing-up milk, an infant cereal, or a baby food product.
  • infant feeding composition a follow-up formula
  • growing-up milk a growing-up milk
  • infant cereal a baby food product.
  • the food product is selected from the group consisting of a beverage product, a yoghurt product, a fermented milk, a fruit juice, or a cereal bar. These food products are well suited for administering the composition to older children and adult humans.
  • the food product is a pet food product.
  • the pharmaceutical or veterinary formulation may be in the form of a tablet, a capsule, granules, or a powder.
  • the composition may be a shelf-stable powder. The low water activity provides this shelf stability and ensures that probiotic micro-organisms, will remain viable even after long storage times.
  • composition comprising the effective amount of the active ingredients or in a separate composition for simultaneous or sequential administration.
  • a package can contain one or more of the servings or doses.
  • compositions are administered in an amount sufficient to at least partially treat or arrest the symptoms of the allergic disorder.
  • An amount adequate to accomplish this is defined as "a therapeutically effective dose”. Amounts effective for this purpose will depend on several factors known to those of skill in the art such as the severity of the disease and the weight and general state of the patient.
  • compositions according to the invention are administered to a patient susceptible to or otherwise at risk of a particular disease in an amount that is sufficient to at least partially reduce the risk of developing a disease.
  • a prophylactic effective dose Such an amount is defined to be "a prophylactic effective dose”.
  • the precise amounts depend on a number of patient-specific factors such as the patient's state of health and weight.
  • epicatechin and probiotic bacteria strain will each be administered in a therapeutically effective dose and/or in a prophylactic effective dose.
  • the composition is administered at least once a day.
  • the composition is preferably administered orally at least 4 weeks before the start of the pollen season.
  • a kit comprising a combination of at least one polyphenol and the at least one probiotic selected from the group consisting of Lactobacillus paracasei and Lactococcus lactis in one or more containers.
  • the one or more containers comprise at least one first container that stores at least one polyphenol separately from at least one probiotic selected from the group consisting of Lactobacillus paracasei and Lactococcus lactis, which is stored in at least one second container, and the kit further comprises instructions for admixing the polyphenol with the probiotic strain into a unit dosage form.
  • the polyphenol is epicatechin, preferably in the form of an apple extract.
  • the Lactobacillus paracasei is LP-33® (GenMont Biotech Inc.) or NCC 2461 (CNCM 1-2116), for example.
  • the Lactococcus lactis strain is NCC 2287 (CNCM 1-4154), for example.
  • the combination can be provided together in one or more prepackaged unit dosage forms, for example in separate containers that each contain a dried powder such that each container contains one prepackaged unit dosage form.
  • the kit can comprise a plurality of compositions for admixing together to form one or more of the compositions disclosed herein.
  • the kit can contain two or more dried powders in separate containers relative to each other, the separate powders each containing a portion of the final unit dosage form.
  • the kit can contain one or more first containers that house at least one epicatechin and can also contain one or more second containers that house the probiotic strain. The content of one of the first containers can be admixed with one of the second containers to form at least a portion of the unit dosage form of the composition.
  • the composition is packed in individual primary packages.
  • the primary package can be a blister pack, a rupturable capsule, a flask, a bottle, a breakable glass ampoule, or any other similar packaging for containing and dispensing one dose of the composition.
  • the primary package is an individual sachet made of a flexible material. The material is preferably a barrier to oxygen and moisture to guarantee a shelf-life of at least 6 months, preferably at least 12 months.
  • the material can be made of a monolayer or multilayer film, with or without a metallic layer, selected within the list of the following materials: cellulose fibers, paper, cardboard, polyolefins, biodegradable polymers such as polylactic acid (PLA), polybutylene succinate (PBS), polybutylene adipate terephthalate (PBAT), polyhydroxy alcanoate (PHA), or a combination thereof. If the material is a multilayer, it can further contain adhesive layers, primers, protective layers, inks.
  • the primary package may contain other bioactive ingredients than those described above, i.e. any other functional ingredient known in the art.
  • the secondary packaging is a carton box comprising a plurality of individual compartments adjacent to one another, as illustrated in figure 1 , each for containing a primary package.
  • Each compartment is closed by a wall that is opened manually by the consumer at the time of consumption of the composition.
  • the wall preferably comprises precuts to detach said wall at least partly.
  • the wall is detachable over three of its sides, so that when detached along the precuts, the fourth side acts as a hinge to create a door-like panel. This prevents packaging material to be fully detached from the rest of the secondary packaging, hence ensuring proper disposal and recyclability of the entire packaging.
  • the composition may be different from one compartment to the other, in terms of dosage, but also in terms of bioactive ingredients that are present into the composition.
  • bioactive ingredients are preferably the one described above but may alternatively be any other functional ingredient.
  • each compartment comprises an information associated with the composition. That information is preferably printed as a QR code or similar type of code.
  • the code is adapted to be read by a sensing device, for instance, the camera of a portable communication device that can then display information retrieved from a remote database.
  • the information can be identical from one compartment to another, but advantageously can be different from one compartment to another, and adapted to each individual intake of the composition.
  • the information (e.g. the QR code) is preferably printed at the inner surface of the detachable wall of each compartment, such that when the consumer opens one compartment, the information can be delivered at the same time as the composition intake.
  • the QR code may also provide educational information, link to website and shop.
  • the website allows to share feedback.
  • the secondary packaging comprises as many compartments as days in a month.
  • the number of compartments can vary from one secondary packaging to another, depending on when it is to be used during the year. This provides the consumer with a way of consuming one dose of the composition, each day, and also benefit from a dedicated information, also for each day of the month. This is particularly advantageous for prevent under-, or over-intakes of the composition, ensuring regularity of intakes throughout the month (monitor daily consumption).
  • Example 1 Food supplement
  • composition is provided as a 2 stick packs to be reconstituted in water.
  • the first 8g stick pack comprises the epicatechin along with mixture of fruit extracts (see Table 1).
  • the second stick pack only contains as active ingredient the probiotic bacteria strain Lactobacillus paracasei strain LP-33® (GenMont Biotech Inc.), in a maltodextrin powder matrix (33% probiotic strain, 67% maltodextrin).
  • the probiotic strain is in an amount of 7.25E10 CFU/g (0.75g total).
  • this date shall be the date on which the status of the International Depository Authority was acquired.
  • this date shall be the date on which the status of the International Depository Authority was acquired.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition destinée à être utilisée dans la prévention de l'allergie respiratoire, en particulier de la rhinite allergique, de l'allergie aux acariens de la poussière et/ou de l'asthme chez les jeunes enfants. L'invention concerne également un kit comprenant une association d'au moins un polyphénol et d'au moins un probiotique choisi dans le groupe constitué par Lactobacillus paracasei et Lactococcus lactis dans un ou plusieurs récipients.
PCT/EP2022/053781 2021-02-23 2022-02-16 Composition et kit pour soulager les symptômes de l'allergie respiratoire chez les jeunes enfants WO2022179905A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2023548866A JP2024506678A (ja) 2021-02-23 2022-02-16 幼児における呼吸器アレルギーの症状を緩和するための組成物及びキット
EP22707068.7A EP4297736A1 (fr) 2021-02-23 2022-02-16 Composition et kit pour soulager les symptômes de l'allergie respiratoire chez les jeunes enfants
AU2022224953A AU2022224953A1 (en) 2021-02-23 2022-02-16 Composition and kit for alleviating symptoms of respiratory allergy in toddlers
US18/547,277 US20240139264A1 (en) 2021-02-23 2022-02-16 Composition and kit for alleviating symptoms of respiratory allergy in toddlers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21158670.6 2021-02-23
EP21158670 2021-02-23

Publications (1)

Publication Number Publication Date
WO2022179905A1 true WO2022179905A1 (fr) 2022-09-01

Family

ID=74797692

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/053781 WO2022179905A1 (fr) 2021-02-23 2022-02-16 Composition et kit pour soulager les symptômes de l'allergie respiratoire chez les jeunes enfants

Country Status (5)

Country Link
US (1) US20240139264A1 (fr)
EP (1) EP4297736A1 (fr)
JP (1) JP2024506678A (fr)
AU (1) AU2022224953A1 (fr)
WO (1) WO2022179905A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024093938A1 (fr) * 2022-11-01 2024-05-10 永泽泰生物科技(北京)有限公司 Combinaison de prébiotique composite et de probiotique composite pour le traitement de la rhinite allergique

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0185833A1 (fr) 1984-12-27 1986-07-02 Audiotecnica Italina srl Membrane en matériaux plastiques pour haut-parleurs
WO2009072889A1 (fr) 2007-12-07 2009-06-11 N.V. Nutricia Bifidobactérie pour une allergie contre les acariens détriticoles
EP2133088A2 (fr) * 2008-06-09 2009-12-16 Nestec S.A. Rooibos et inflammation
US20120114608A1 (en) * 2008-02-06 2012-05-10 James Patrick Ebel Compositions, methods and kits for enhancing immune response to a respiratory condition
US20120148629A1 (en) * 2009-08-18 2012-06-14 Nestec S.A. Nutritional composition comprising lactococcus strains and reducing allergy symptoms, especially in infants and children
EP2747584A1 (fr) 2011-08-24 2014-07-02 Nestec S.A. Épicatéchine utilisée pour soulager les symptômes de l'allergie
US20160303226A1 (en) * 2013-11-25 2016-10-20 Nestec S.A. Heat-treated formulation of bifidobacterium lactis ncc 2818 reduces allergic manifestations

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0185833A1 (fr) 1984-12-27 1986-07-02 Audiotecnica Italina srl Membrane en matériaux plastiques pour haut-parleurs
WO2009072889A1 (fr) 2007-12-07 2009-06-11 N.V. Nutricia Bifidobactérie pour une allergie contre les acariens détriticoles
US20120114608A1 (en) * 2008-02-06 2012-05-10 James Patrick Ebel Compositions, methods and kits for enhancing immune response to a respiratory condition
EP2133088A2 (fr) * 2008-06-09 2009-12-16 Nestec S.A. Rooibos et inflammation
US20120148629A1 (en) * 2009-08-18 2012-06-14 Nestec S.A. Nutritional composition comprising lactococcus strains and reducing allergy symptoms, especially in infants and children
EP2747584A1 (fr) 2011-08-24 2014-07-02 Nestec S.A. Épicatéchine utilisée pour soulager les symptômes de l'allergie
US20160303226A1 (en) * 2013-11-25 2016-10-20 Nestec S.A. Heat-treated formulation of bifidobacterium lactis ncc 2818 reduces allergic manifestations

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARSLANOGLU ET AL., J NUTR, vol. 138, 2008, pages 1091 - 1095
DUNSTAN ET AL., J ALLERGY CLIN IMMUNOL, vol. 112, 2003, pages 1178 - 1184
KALLIOMAKI ET AL., LANCET, vol. 357, 2001, pages 1076 - 9
SINGH A. ET AL: "Increased IL-5 And IL-13 Cytokine Levels In Ex Vivo Stimulated Whole Blood Cells From Grass Pollen Allergic Donors Correlates With Seasonal Severity Of Pollen Exposure", 19 February 2011 (2011-02-19), J ALLERGY CLIN IMMUNOL, VOLUME 127, NUMBER 2, p: AB53, Abstract Nr: 196, XP055811801, Retrieved from the Internet <URL:https://www.sciencedirect.com/journal/journal-of-allergy-and-clinical-immunology/vol/127/issue/2/suppl/S> DOI: https://doi.org/10.1016/j.jaci.2010.12.223 *
XIAO JZ ET AL.: "Effect of probiotic Bifidobacterium longum BB536 in relieving clinical symptoms and modulating plasma cytokine levels of Japanese cedar pollinosis during the pollen season. A randomized double-blind, placebo-controlled trial", J INVESTIG ALLERGOL CLIN IMMUNOL, vol. 16, no. 2, 2006, pages 86 - 93, XP002500162
YANNICK PERRIN ET AL: "Comparison of two oral probiotic preparations in a randomized crossover trial highlights a potentially beneficial effect of Lactobacillus paracasei NCC2461 in patients with allergic rhinitis", CLINICAL AND TRANSLATIONAL ALLERGY, BIOMED CENTRAL LTD, LONDON, UK, vol. 4, no. 1, 6 January 2014 (2014-01-06), pages 1, XP021177223, ISSN: 2045-7022, DOI: 10.1186/2045-7022-4-1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024093938A1 (fr) * 2022-11-01 2024-05-10 永泽泰生物科技(北京)有限公司 Combinaison de prébiotique composite et de probiotique composite pour le traitement de la rhinite allergique

Also Published As

Publication number Publication date
AU2022224953A9 (en) 2024-05-09
AU2022224953A1 (en) 2023-07-20
EP4297736A1 (fr) 2024-01-03
JP2024506678A (ja) 2024-02-14
US20240139264A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
Shinde et al. Nutraceuticals: A Review on current status
US7115297B2 (en) Nutritionally fortified liquid composition with added value delivery systems/elements/additives
RU2605330C2 (ru) Способы и композиции, подходящие для укрепления здоровья кожи
JP6204913B2 (ja) アレルギーの症状を軽減するためのエピカテキン
CN101939411A (zh) 用于提高呼吸病症免疫应答的组合物、方法和试剂盒
JP2012504554A (ja) エネルギー代謝を向上させる方法
CN111249371A (zh) 解酒护肝组合物及产品
US20240139264A1 (en) Composition and kit for alleviating symptoms of respiratory allergy in toddlers
CN111787925A (zh) N-乙酰神经氨酸组合物和使用方法
US20240122998A1 (en) Composition and kit for alleviating symptoms of respiratory allergy
CN103917230A (zh) 改善应激引起的症状或情况的方法
US20040105849A1 (en) Treatment for SMA disease
Mindell et al. Earl Mindell's New Vitamin Bible
MORSHEDI et al. Chronic consumption of kombucha and black tea prevents weight loss in diabetic rats
US20240165183A1 (en) Methods and compositions for microencapsulated compounds
Rosen “The Gripe”: An integrative approach to infant colic
JP2015010041A (ja) 抗アレルギー剤
Dean A preliminary review of US nutraceutical patent trends-before and after DSHEA
Frank et al. {BLR 2855} FDA—Labeling—Nutraceuticals: Nutraceuticals—Food, Dietary Supplement, or Drug?

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22707068

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022224953

Country of ref document: AU

Date of ref document: 20220216

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023014798

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2023548866

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 18547277

Country of ref document: US

ENP Entry into the national phase

Ref document number: 112023014798

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20230724

WWE Wipo information: entry into national phase

Ref document number: 2022707068

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022707068

Country of ref document: EP

Effective date: 20230925